“And near term, we expect soon approval for etrasimod and another readout.”

In context

“ave full ex U.S. and ex Japan rights and we earned royalties on the U.S. and Japan sales. So, taken together, this collaboration allows us to keep more than 50% of the total value of TL1A with zero incremental R&D spend. And for a Phase 2 program, we feel this is a very sound move for Pfizer shareholders. Dr. Albert Bourla: Mikael, anything to add here? Dr. Mikael Dolsten: Aamir, said it well. And I just wanted to punctuate among the very many options, we have a strong platform in bispecific in many therapeutic, including in immunology and we do have TL1A antibody. That would be very interesting, where we own an even greater share. We have triple specifics that are going into atopic dermatitis. So it just punctuates. Even in the very same therapeutic area, we have so many things going on. And near term, we expect soon approval for etrasimod and another readout [indiscernible]. So a lot to start there. Dr. Albert Bourla: Thank you, Mikael. Don’t tip competition too much about what we have in our pocket. So let’s go to the next question. Operator: Next, we have Steve Scala with Cowen. Steve Scala: I just have an observation than a question, but the observation is that it’s still not clear what has changed in your long-term COVID expectations versus when you first gave the $30 billion guidance 6 months ago since in the prior 6 months, nothing really has changed other than FDA action, which doesn’t impact the long term. So, that’s just an observation. But my question is on Vyndaqel. Vyndaqel has become a very important franchise, yet its exclusivity is not long in either the U.S. or the EU. Are there any strategies to get around the LOEs, or is it s”